You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201451 - 201460 of 205243 results
  1. Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga

    SBC: Enantigen Therapeutics            Topic: NIAID

    DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, which is essential for the subsequent viral DNA ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A novel, multiparametric cardiac safety assay using human myocytes

    SBC: THERAPYX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine against it, and resistance even to the latest generations of antibiotics continues to emerge. New findin ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Hybrid Bioanalytical System

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Molecular Express specializes in the design and engineering of functionalized liposomes for drug delivery and vaccine development. In previous studies, an extensive set of liposome formulations were screened to establish the optimal lipid combination that meets certain physicochemical parameters and provides strong immune responses in animals. These unilamellar ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Prevention of mosquito-borne illness through manipulation of the CO2 receptor

    SBC: OLFACTOR LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): A key component to combating mosquito-borne illnesses is prevention from acquiring the disease. Current mosquito repellents, such as Permethrin and DEET, have been shown to be too costly and mosquitoes can eventually develop resistance to them. In this proposal, Olfactor Laboratories Inc. (OLI) supports the development of novel, spatial, non-insecticidal mosqui ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Ultrasensitive Detection of Hepatitis Viruses by Immunoassay Amplification

    SBC: BCR DIAGNOSTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This proposal responds to the action plan for combating the Silent Epidemic of Viral Hepatitis recently launched by the National Institutes of Health by focusing on early diagnosis of hepatitis, which is crucial for preventing further infections and to improve therapy. Approximately 170 million people are infected with HCV, many of whom develop cirrhosis and l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Novel screen to identify arenavirus inhibitors

    SBC: RETROVIROX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Lassa fever virus (LASV) and other members of the arenavirus family are important human pathogens that can cause hemorrhagic fevers with mortality rates over 20%. Because their aerosol transmissibility and elevated morbidity and mortality, LASV and pathogenic strains of Junin virus (JUNV) pose a bioterrorism risk and are in the list of high priority Category A ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Neural Probe for high spatial and temporal resolution detection of cocaine and su

    SBC: Enantigen Therapeutics            Topic: NIAID

    DESCRIPTION (provided by applicant): This is a proposal to implement a novel high throughput assay system to detect inhibitors of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) formation and/or maintenance. HBV cccDNA is essential to the virus life cycle and its elimination during chronic infection is considered critical to durable therapy. However, because of the limitations of c ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Micro_patterned Surfaces for Reducing the Risk of Ventilator_Associated Pneumonia

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): A highly effective vaccine that targets the asymptomatic sporozoite (SPZ) and liver stages of the most lethal human malaria parasite, Plasmodium falciparum (Pf), would be an ideal tool to prevent malaria infection, disease and transmission. After 3 decades of effort, the most effective subunit malaria vaccine only provides 50% protection against infection at 2 ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord

    SBC: PROGNOSYS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is a need for new proteomics technologies to enable multiplexed assays of immune system response. We aim to develop a novel technology for this application that is based on simultaneously measuring the binding ofmany customizable in silico-defined peptides. This technology could be applied to identify epitopes from pathogens, autoantigens, allergens or tu ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Therapy Management Software for Naturalistic Model-Based Behavioral Interventions

    SBC: GENESEGUES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a safe and effective topical vaccine against the dengue virus (DENV). DENV causes an estimated 30 to 50 million cases of debilitating fever leading to over 20,000 deaths worldwide every year. DNA-based vaccines have great potential against DENV because they can more quickly generate a balanced immune response, are ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government